title: Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology Study.
abstract: Brain monoamines (serotonin, norepinephrine, dopamine, and histamine) play an important role in emotions, cognition, and pathophysiology and treatment of mental disorders. The interactions between serotonin, norepinephrine, and dopamine were studied in numerous works; however, histamine system received less attention. The aim of this study was to investigate the interactions between histamine and other monoamines, using in vivo microdialysis and electrophysiology. It was found that the inverse agonist of histamine-3 receptors, thioperamide, increased the firing activity of dopamine neurons in the ventral tegmental area. Selective agonist of histamine-3 receptors, immepip, reversed thiperamide-induced stimulation of firing activity of dopamine neurons. The firing rates of serotonin and norpeinephrine neurons were not attenuated by immepip or thioperamide. Thioperamide robustly and significantly increased extracellular concentrations of serotonin, norepinephrine, and dopamine in the rat prefrontal cortex and slightly increased norepinephrine and dopamine levels in the tuberomammillary nucleus of the hypothalamus. It can be concluded that histamine stimulates serotonin, norepinephrine, and dopamine transmission in the brain. Modulation of firing of dopamine neurons is a key element in functional interactions between histamine and other monoamines. Antagonists of histamine-3 receptors, because of their potential ability to stimulate monoamine neurotransmission, might be beneficial in the treatment of mental disorders.
authors.affiliation: Brains On-Line BV, De Mudden 16, 9747 AW, Groningen, The Netherlands.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Flik
authors.forename: Joost H A
authors.initials: JH
authors.lastname: Folgering
authors.forename: Thomas I H F
authors.initials: TI
authors.lastname: Cremers
authors.forename: Ben H C
authors.initials: BH
authors.lastname: Westerink
authors.forename: Eliyahu
authors.initials: E
authors.lastname: Dremencov
mesh_terms: D000200:Action Potentials; D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000502:physiology; D004298:Dopamine / Q000378:metabolism*; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D006632:Histamine / Q000378:metabolism*; D017442:Histamine Agonists / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D018100:Receptors, Histamine H3 / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*
chemical_list: D017442:Histamine Agonists; D018100:Receptors, Histamine H3; D012701:Serotonin; D006632:Histamine; D004298:Dopamine; D009638:Norepinephrine
references.citation: J Neurochem. 1998 Apr;70(4):1750-8
references.pmid: 9523594
references.citation: Brain Res. 2002 Feb 1;926(1-2):172-5
references.pmid: 11814420
references.citation: J Pharmacol Exp Ther. 2005 Apr;313(1):176-90
references.pmid: 15608077
references.citation: J Comp Neurol. 1989 Aug 15;286(3):289-310
references.pmid: 2768560
references.citation: Neuropsychopharmacology. 2004 Apr;29(4):705-17
references.pmid: 14735131
references.citation: Eur J Neurosci. 2009 Jun;29(12):2363-74
references.pmid: 19490084
references.citation: Eur J Pharm Sci. 2004 Sep;23 (1):89-98
references.pmid: 15324926
references.citation: Nat Rev Neurosci. 2013 Jul;14(7):472-87
references.pmid: 23783198
references.citation: Trends Pharmacol Sci. 1998 May;19(5):177-83
references.pmid: 9652190
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2000 Feb;24(2):275-84
references.pmid: 10800750
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1977 Mar;297(1):1-7
references.pmid: 193046
references.citation: J Neurosci. 1996 Feb 15;16(4):1523-37
references.pmid: 8778302
references.citation: J Pharmacol Exp Ther. 2011 Jan;336(1):38-46
references.pmid: 20864505
references.citation: Br J Pharmacol. 2009 May;157(1):55-63
references.pmid: 19413571
references.citation: Farmaco. 1997 Jun-Jul;52(6-7):457-62
references.pmid: 9372598
references.citation: J Comp Neurol. 1994 Sep 1;347(1):101-14
references.pmid: 7798375
references.citation: Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):289-98
references.pmid: 9379777
references.citation: Psychopharmacology (Berl). 2011 Feb;213(2-3):441-52
references.pmid: 19823805
references.citation: Eur J Pharmacol. 2005 Jan 4;506(3):237-40
references.pmid: 15627433
references.citation: Nature. 1983 Apr 28;302(5911):832-7
references.pmid: 6188956
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):141-7
references.pmid: 14687868
references.citation: Neurosci Lett. 2002 Mar 8;320(3):133-6
references.pmid: 11852180
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1998 Oct;358(4):423-9
references.pmid: 9826064
references.citation: Brain Res. 1990 Sep 3;526(2):322-7
references.pmid: 1979518
references.citation: Psychopharmacology (Berl). 2007 Sep;194(1):63-72
references.pmid: 17530476
references.citation: J Neurosci. 2005 Jan 5;25(1):88-95
references.pmid: 15634770
references.citation: Brain Res. 1996 Dec 16;743(1-2):178-83
references.pmid: 9017245
references.citation: Clin Allergy Immunol. 2002;17:27-64
references.pmid: 12113220
references.citation: Brain Res. 1978 Nov 10;156(2):275-91
references.pmid: 213164
references.citation: Nucl Med Biol. 2006 Aug;33(6):801-10
references.pmid: 16934699
references.citation: Neuroscience. 1993 Jan;52(1):169-89
references.pmid: 8381924
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1994 Jul;350(1):34-41
references.pmid: 7935852
references.citation: Neuroscience. 1989;28(3):585-610
references.pmid: 2710333
references.citation: Prog Neurobiol. 2001 Apr;63(6):637-72
references.pmid: 11164999
references.citation: J Psychiatry Neurosci. 2009 May;34(3):223-9
references.pmid: 19448853
references.citation: J Comp Neurol. 1988 Jul 8;273(2):163-86
references.pmid: 3417901
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45
references.pmid: 17327487
references.citation: Int J Neuropsychopharmacol. 2008 Aug;11(5):625-39
references.pmid: 18205979
references.citation: Neurotox Res. 2008 May-Jun;13(3-4):231-40
references.pmid: 18522902
references.citation: J Pharmacol Exp Ther. 1973 Jun;185(3):560-71
references.pmid: 4576427
references.citation: J Sex Med. 2010 May;7(5):1757-67
references.pmid: 20163532
references.citation: CNS Neurosci Ther. 2010 Jun;16(3):e1-17
references.pmid: 20406250
references.citation: J Med Chem. 1994 Feb 4;37(3):332-3
references.pmid: 8308858
references.citation: Brain Res Bull. 1993;32(3):267-72
references.pmid: 8374806
references.citation: J Pharmacol Exp Ther. 2010 Jan;332(1):164-72
references.pmid: 19815811
references.citation: Biol Psychiatry. 2007 Mar 1;61(5):671-8
references.pmid: 16934772
references.citation: Fundam Clin Pharmacol. 1994;8(2):128-37
references.pmid: 8020871
references.citation: Physiol Rev. 2008 Jul;88(3):1183-241
references.pmid: 18626069
references.citation: Br J Pharmacol. 1990 Nov;101(3):621-4
references.pmid: 1963802
references.citation: Eur J Neurosci. 2011 Dec;34(11):1747-55
references.pmid: 22050612
references.citation: Curr Opin Allergy Clin Immunol. 2012 Oct;12(5):510-6
references.pmid: 22918191